Abstract 2051P
Background
The implementation process, characteristics and objectives of the companion program have been previously reported. Briefly, the program consisted of a web containing an e-PRO questionnaire platform with real time monitoring for early symptom detection and intervention, a communication channel for resolving doubts and educational resources on diagnosis, treatment and adverse events. We aimed to determine the impact of the program in terms of reduction of emergency visits (ERV) and non-planned inpatient admissions (NIA).
Methods
Case-control analysis of patients with gastrointestinal cancer receiving systemic treatment (chemotherapy, immunotherapy, targeted therapy or combinations) at Oncosalud between June 2021 and July 2022. Patients were divided into two cohorts according to enrollment into the companion. Incidence rate (IR), IR ratios (IRR) and 95% confidence intervals were calculated. Time to first ERV and NIA curves since enrollment were constructed using the Kaplan Meier method and log rank test.
Results
In total, 199 patients were included, 97 enrolled into the program (cases). Mean age was 61.4 (±13.2), 50.3% were women and 94% were in ECOG 1-2. Chemotherapy was the most common treatment (88.4%). There were no differences in these characteristics between groups. The mean follow time was of 8.3 and 6.7 months, for cases and controls respectively. A statistically significant reduction in incidence rates was observed for both outcomes. ERV IR was 20.3 ERV per month in controls (95% CI:17.0-24.0) vs 15.1 ERV per month in cases (95%CI:12.6-18.0) which translated into a 25% decrease in ERV (IRR: 0.75 (95%CI:0.58-0.96; p=0.02)). NIA IR was 9.2 NIA per month in controls (95%CI:7.0-11.8) vs 5.9 NIA per month in cases (95%CI:4.4-7.8) which translated into a 35% decrease in NIA (IRR: 0.65 (95%CI:0.44-0.96; p=0.02)). There were no differences in time to first event for both outcomes.
Conclusions
The results demonstrate that e-PRO monitoring within a comprehensive companion program for cancer patients undergoing systemic treatment achieves clinical benefits as it reduces ERV and NIA. Its potential impact on outcomes and costs is being evaluated and will be reported.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Oncosalud.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2066P - Evaluation of the quality and reliability of ChatGPT and Perplexity's responses about rectal cancer
Presenter: Ozan Yazici
Session: Poster session 06
2067P - Influence of psychiatric disorders on survival in patients with lung cancer: Real-world data
Presenter: Tomi Kovacevic
Session: Poster session 06
2068P - Perspectives and concerns on sexuality among adolescents and young adults treated for testicular germ cell tumour: The PRICELESS-study - A qualitative study
Presenter: Danielle Zweers
Session: Poster session 06
2069P - QoL changes of caregivers during first-line palliative chemotherapy for patients with incurable cancer
Presenter: Nobumichi Takeuchi
Session: Poster session 06
2070P - Assessment of healthy lifestyle habits in breast cancer patients
Presenter: Juan Cristobal Sanchez
Session: Poster session 06
2071P - Identification of top issues and concerns of cancer patients in Korea on social media
Presenter: Joo Han Lim
Session: Poster session 06
2072P - Topical application of mixed agents to reduce oral mucositis during radiotherapy in post operated head and neck cancer
Presenter: Chandra Prakash
Session: Poster session 06
2073P - Medical cannabis: A potential effective treatment for chemotherapy-induced peripheral neuropathy (CIPN)
Presenter: Ravit Geva
Session: Poster session 06
2074P - Oral cannabidiol for prevention of chemotherapy-induced peripheral neuropathy
Presenter: Sebastian Nielsen
Session: Poster session 06